Publications arising directly from the work of the Pancare Foundation or from programs and scholarships funded by Pancare. You will also find reviews of articles in the media, by members of our medical advisory board These articles may be of interest to health professionals in the areas of pancreatic, liver, biliary, oesophageal and stomach cancer control.
N Waddell, M Pajic, A Patch, D Chang, K Kassahn, P Bailey, A Johns, D Miller, K Nones, K Quek, M Quinn, A Robertson, M Fadlullah, T Bruxner, A Christ, I Harliwong, S Idrisoglu, S Manning, C Nourse, E Nourbakhsh, S Wani, P Wilson, E Markham, N Cloonan, M Anderson, L Fink, Oliver Holmes , Stephen Kazakoff , Conrad Leonard , Felicity Newell , S Song, D Taylor, S Wood, Q Xu, J Wu, M Pinese, M Cowley, M Jones, E Colvin, A Nagrial, E Humphrey, L Chantrill, A Mawson, J Humphris, A Chou, C Scarlett, A Pinho, I Rooman, J Samra, J Kench, J Lovell, N Merrett, C Toon, K Epari, N Nguyen, A Barbour, N Zeps, N Jamieson, J Graham, R Gruetzmann, R Hruban, A Maitra, C Iacobuzio-Donahue, C Wolfgang, R Morgan, R Lawlor, V Corbo, C Bassi, M Falconi, G Zamboni, G Tortora, M Tempero, J Eshleman, C Pilarsky, A Scarpa, E Musgrove, M Giry-latterriere, A Gill, J Pearson, S Grimmond, D Aust , V Chin et al. Whole Genomes Redefine the Mutational Landscape of Pancreatic Cancer. Nature 2015
V T Chin, AM Nagrial, AChou, AV Biankin, P Timpson, M Pajic. Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. Experts in Molecular Medicine (under review)
Sjoquist K, Chin VT et al. Personalising pancreas cancer treatment: when tissue is the issue. World Journal of Gastroenterology 2014 Jun 28;20(24):7849-63
Nagrial A, Chin VT et al. Second-Line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. (Under review)
Pajic M, Herrmann D, Vennin C, Conway J, Chin VT et al. The dynamics of Rho GTPase signalling and implications for targeting cancer and the tumour microenvironment. (Invited commentary, accepted for publication)
Weinberg L, Houli N, Nikfarjam M. Improving outcomes for pancreatic cancer: radical surgery with patient-tailored, surgery-specific advanced haemodynamic monitoring. BMJ Case Rep. 2013 Apr 30;2013
Yeo D, Huynh N, Beutler J.A, Baldwin G.S, He H, Nikfarjam M. Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model. Journal of Investigative Surgery, Early Online, 1-7, 2016
“Pancreatic cancer stem cells could be “suffocated” by an anti-diabetic drug” – Queen Mary University of London
Review by Daniel Croagh MBBS PhD FRACS
“Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers” –
Hans Vasen, Isaura Ibrahim, Carmen Guillen Ponce, Emily P. Slater, Elvira Matthai, Alfredo Carrato, Julie Earl, Kristin Robbers, Anneke M. van Mil, Thomas Potjer, Bert A. Bonsing, Wouter H. de Vos tot Nederveen Cappel, Wilma Bergman, Martin Wasser, Hans Morreau, G¨unter Kl¨oppel, Christoph Schicker, Martin Steinkamp, Jens Figiel, Irene Esposito, Evelina Mocci, Enrique Vazquez-Sequeiros, Alfonso Sanjuanbenito, Maria Muñoz-Beltran, Jos´e Montans, Peter Langer, Volker Fendrich, and Detlef K. Bartsch.
Review by Mehrdad Nikfarjam, MD, PhD, FRACS
Angus G Dalgleish*,1, Justin Stebbing 2, Douglas JA Adamson 3, Seema Safia Arif 4, Paolo Bidoli 5, David Chang 6, Sue Cheeseman 7, Robert Diaz-Beveridge 8, Carlos Fernandez-Martos 9, Rob Glynne-Jones 10, Cristina Granetto 11, Bartomeu Massuti 12, Karen McAdam 13, Raymond McDermott 14, Andre´s J Mun˜oz Martı´n 15, Demetris Papamichael 16, Roberto Pazo-Cid 17, Jose M Vieitez 18, Alberto Zaniboni 19, Kevin J Carroll 20, Shama Wagle 20, Andrew Gaya 21 and Satvinder S Mudan 22
(1)Cancer Vaccine Institute, St George’s University of London, London, UK; (2) Department of Oncology, Imperial College, Hammersmith Hospital, London, UK; (3) Department of Oncology, Ninewells Hospital, Dundee, UK; (4) Velindre Cancer Centre, Cardiff, UK; (5) Department of Oncology, Azienda Ospedaliera San Gerardo, Monza, Italy; (6) Department of General Surgery, Royal Blackburn Hospital, Blackburn, UK; (7) Department of Oncology, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK; (8) Me´dico Adjunto de Oncologı´a Me´dica, Hospital La Fe de Valencia, Valencia, Spain; (9) Instituto Valenciano de Oncologia, Valencia, Spain; (10) Mount Vernon Cancer Centre, Northwood, UK; (11) Medical Oncology, Azienda Ospedaliera Santa Croce e Carle, Cuneo, Italy; (12) Ensayos Clı´nicos Oncologı´a, Hospital General Universitario de Alicante, Alicante, Spain; (13) Oncology Department, Peterborough and Stamford Hospitals NHS Trust, Peterborough, UK; (14) Medical Oncology, St Vincent’s University Hospital and The Adelaide and Meath Hospital, Dublin, Republic of Ireland; (15) Gastrointestinal Cancer Unit, Hospital General Universitario Gregorio Maran˜ o´n, Madrid, Spain; (16) Department of Medical Oncology, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; (17) Servicio de Oncologı´a Me´dica, Hospital Miguel Servet, Zaragoza, Spain; (18) Area and Neuroendocrine Tumors Gastrointestinal Medical Oncology, Hospital Central de Asturias, Asturias, Spain; (19) Oncology Department, Fondazione Poliambulanza, Brescia, Italy; (20) TranScrip Partners LLP, Reading, UK; (21) Clinical Oncology, Guy’s & St Thomas’ Hospitals NHS Trust, London, UK and (22) St George’s University of London, Imperial College, London and The Royal Marsden Hospital, London, UK.
